The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

Matt Price drove his 73-year-old father Stephen from their New Jersey home to a medical strip mall on the Jersey Shore, for ...

Johnson & Johnson’s Spravato gains FDA approval for standalone depression treatment ahead of Q4 earnings. JNJ stock shows short-term bullish signals, but long-term trends remain bearish ahead of ...

For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety and efficacy profile of nipocalimab for generalized myasthenia gravis (gMG).

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

Johnson & Johnson has a strong business ... and a new law in the U.S. that gives Medicare the power to negotiate drug prices. The first round of negotiations will target three of the company's ...

Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.